Novo Nordisk B

Explore how Novo Nordisk’s share‑repurchase, Wegovy’s pricing gap, and modest earnings outlook shape investor sentiment amid market volatility.

Wegovy HD’s FDA approval boosts Novo Nordisk’s obesity lineup, delivering up to 20.7 % weight loss and positioning it to rival Lilly’s Mounjaro in the U.S. market.

New Nordisk’s stock jumps 10 % as FDA approves Wegovy tablet, opening a new U.S. revenue stream and boosting investor optimism.

Novo Nordisk’s first oral GLP‑1 weight‑management pill, Wegovy® pill, hits FDA and EMA approvals, expands to India, and could shift its stock outlook.

Novo Nordisk B, a leading Danish pharmaceutical company, is undergoing a major governance overhaul after a prolonged dispute with its primary shareholder, the Novo Nordisk Foundation, over the future composition and strategic direction of the board.

Novo Nordisk’s stock price plummeted 6.4% after former US President Donald Trump announced a plan to reduce tariffs on fertility treatments and the medication Ozempic, potentially undermining the company’s pricing power in the US market.